KRAS WT responds better to treatment compared to KRAS mutated colorectal cancers.doi:10.1016/j.ajme.2014.01.003Bader, TalhaMedical Oncology Comprehensive Cancer Centre, King Fahd Medical City, P.O. Box 59046, Riyadh 11525, Saudi Arabia;Ismail, Abdelsalam...
This finding was confirmed in two independent colon cancer cell lines HCT116 (KRAS mutant) and HKe3 (KRAS WT). In all three cell lines, circRNAs were also found in secreted extracellular-vesicles, and circRNAs were more abundant in exosomes than cells. Our results suggest that circRNAs may ...
a, Colony formation assay forKRASWTandKRASG12VSW48 colorectal cancer cell lines after 2 weeks’ exposure to a concentration range of FTD in vitro.b, As ina, but forKRASWTandKRASG12Disogenic Colo320 CRC cell lines.c, Dose–response curves ofKRASWT(black) andKRASG12(red) isogenic SW48 (...
NewsAnti cancer drugsColon cancerColorectal cancerMonoclonal antibodiesMutationNon-small cell lung cancerPhase I clinical trials (Clinical trial)
The KRAS mutant proteins that drive cancer development are highly similar in sequence and structure based on the structural, mutational, and biochemical data of Harvey-RAS (HRAS). Direct inhibitors are most likely to bind to the catalytic domain of KRAS [40]. Research on direct inhibition of KR...
Colorectal cancer (CRC) is among the most commonly diagnosed cancers affecting both genders in the world. It is characterized by genetic instability, which drives tumor formation via the activation of oncogenes, such as KRAS and B-RAF. Approximately 40%
今天,我们特别关注美国康奈尔医学院陈水冰教授、Todd Evans教授团队于2023年12月26日发表在《Cell Stem Cell》(IF:23.9)的经典研究——A pancreatic cancer organoid platform identifies an inhibitor specific to mutant KRAS,该研究通过CRISPR/Cas9的技术构建等基因突变胰腺类器官,利用胰腺类器官进行高通量药物筛选研究,...
Patient Enrollment View LargeDownload mCRC Indicates metastatic colorectal cancer, wt, wild-type. Figure 2. Kaplan-Meier Estimates of Progression-Free Survival View LargeDownload A, Progression-free survival among patients with wild-type (wt) KRAS exon 2 (log-rank P = .06). B, Progression...
[68]. In colon cancer, mutant KRAS has been shown to inhibit expression of interferon regulatory factor2 (IRF2), which is required for interferon-mediated immune responses [69]. Liu et al. analyzed the tumour immune landscape 528 patients with colon cancer (224 KRASmtand 304 KRASwt) and ...
Background Molecular alterations are well studied in colon cancer, however there is still need for an improved understanding of their prognostic impact. This study aims to characterize colon cancer with regard to KRAS, BRAF, and PIK3CA mutations, microsatellite instability (MSI), and average DNA cop...